When Remicade stops working for Crohn’s disease — and it does for a significant number of patients — the most effective next step is switching to a biologic that targets a completely different pathway rather than trying another TNF blocker. Risankizumab, marketed as Skyrizi, has emerged as the strongest option backed by clinical evidence. In the SEQUENCE head-to-head trial published in the New England Journal of Medicine in July 2024, risankizumab achieved endoscopic remission in 31.8 percent of patients who had already failed anti-TNF therapy, nearly double the 16.2 percent seen with ustekinumab. That kind of separation in a rigorous trial has shifted how gastroenterologists think about sequencing therapy after Remicade failure. But risankizumab is not the only option worth knowing about.
Tremfya, another IL-23 inhibitor, received FDA approval for Crohn’s disease in March 2025 and offers flexible dosing that some patients may prefer. Rinvoq, an oral JAK inhibitor that is not technically a biologic, has shown strong results even in patients who have cycled through multiple drug classes. And established agents like Entyvio and Stelara remain in the mix, though newer data suggests they may no longer be the first choices after TNF failure. This article walks through each of these options with the actual trial data behind them, compares their strengths and limitations, and explains why 2026 treatment guidelines now formally recommend switching mechanisms rather than swapping one TNF blocker for another. If you or someone you care for has hit a wall with Remicade, the landscape has changed considerably in the last two years — and there are concrete reasons for cautious optimism.
Table of Contents
- Why Does Remicade Fail, and Which Biologics Work for Crohn’s Disease When It Does?
- Skyrizi After Remicade — What the Trial Data Actually Shows
- Tremfya — The Newest IL-23 Inhibitor With Flexible Dosing
- Rinvoq — An Oral Alternative That Is Not a Biologic
- Why Switching TNF Blockers After Remicade Usually Falls Short
- Entyvio and Stelara — Still in the Picture, But No Longer Front of the Line
- Where Crohn’s Treatment Is Headed After Remicade Failure
- Conclusion
- Frequently Asked Questions
Why Does Remicade Fail, and Which Biologics Work for Crohn’s Disease When It Does?
Remicade, the brand name for infliximab, works by blocking tumor necrosis factor alpha, a protein that drives inflammation. The problem is that somewhere between 30 and 50 percent of patients either do not respond initially or gradually lose response over time, often because they develop antibodies against the drug. For years, the reflexive next move was to try another TNF blocker — adalimumab or certolizumab — but outcomes with that strategy have been underwhelming. The inflammatory process in Crohn’s disease involves multiple pathways, and if one patient’s disease is being driven primarily by interleukin-23 rather than TNF-alpha, no amount of TNF blockade will get the job done. This is why the 2026 treatment guidelines now recommend switching to a different mechanism of action after Remicade failure rather than cycling through TNF blockers. The biologics with the most robust evidence in this specific population — patients who have already tried and failed a TNF inhibitor — are the IL-23 inhibitors risankizumab and guselkumab, along with the oral JAK inhibitor upadacitinib.
Each targets a fundamentally different node in the inflammatory cascade. Risankizumab and guselkumab block IL-23, a cytokine that sits upstream of many inflammatory processes in the gut. Upadacitinib works inside the cell, inhibiting Janus kinase enzymes that relay signals from multiple cytokines simultaneously. These are not incremental tweaks — they represent genuinely different approaches to the disease. The practical difference shows up in the numbers. In the MOTIVATE trial, which enrolled only patients who had already failed biologic therapy, 42 percent achieved clinical remission with risankizumab at week 12 compared to 20 percent with placebo. In the U-EXCEED induction trial, which was enriched for biologic-failure patients, upadacitinib produced clinical remission in 38.9 percent versus 21.1 percent with placebo. These are not cure rates, but for a population that had already exhausted one or more lines of therapy, they represent meaningful ground gained.
Skyrizi After Remicade — What the Trial Data Actually Shows
Risankizumab has accumulated the deepest evidence base among the newer options for post-TNF-failure Crohn’s disease. The story starts with two induction trials. ADVANCE enrolled a mixed population and found that 45 percent of patients receiving risankizumab 600 milligrams intravenously achieved clinical remission at week 12, compared to 25 percent on placebo. MOTIVATE, which specifically selected patients who had failed biologic therapy, showed a tighter but still significant gap — 42 percent versus 20 percent. After induction, the FORTIFY maintenance trial demonstrated that 55 percent of responders maintained clinical remission at one year on the 180 milligram subcutaneous dose, compared to 41 percent in the withdrawal group. The data that truly changed the conversation, however, came from the SEQUENCE trial — a head-to-head comparison against Stelara in 520 patients who had failed anti-TNF therapy. At week 48, risankizumab achieved endoscopic remission in 31.8 percent of patients versus 16.2 percent for Stelara.
Clinical remission rates at week 48 were 60.8 percent versus 40.8 percent. The endoscopic remission finding matters enormously because mucosal healing is the best predictor of long-term outcomes in Crohn’s disease; feeling better is important, but actual healing of the intestinal lining is what reduces hospitalizations, surgeries, and disease complications down the road. However, a few caveats deserve mention. The SEQUENCE trial compared risankizumab to ustekinumab, not to the other newer agents. We do not yet have head-to-head data pitting risankizumab against guselkumab or upadacitinib. Additionally, the 31.8 percent endoscopic remission rate, while clearly superior in context, still means that roughly two-thirds of patients did not achieve that endpoint. Risankizumab is the best-studied option in this population, but it is not a universal solution — and patients with certain disease phenotypes, stricturing behavior, or extensive prior surgical history may respond differently than the trial populations suggest.
Tremfya — The Newest IL-23 Inhibitor With Flexible Dosing
Guselkumab, sold as Tremfya, received FDA approval for moderately to severely active Crohn’s disease on March 20, 2025, making it the newest biologic in this space. It targets the same IL-23 pathway as risankizumab but is a distinct antibody with its own pharmacologic profile. Its approval was supported by the GALAXI program: GALAXI 2 showed 47 percent clinical remission at week 12 versus 20 percent with placebo, and GALAXI 3 showed 47 percent versus 15 percent. These numbers put it in a competitive range with risankizumab’s induction data, though cross-trial comparisons are inherently limited by differences in patient populations and study design. What sets Tremfya apart is its dosing flexibility. It is the first and only IL-23 inhibitor approved with both subcutaneous and intravenous induction options for Crohn’s disease. Induction involves 400 milligrams subcutaneously at weeks zero, four, and eight, followed by maintenance dosing of either 200 milligrams every four weeks or 100 milligrams every eight weeks.
For patients who strongly prefer to avoid infusion centers — which can require hours of travel and scheduling coordination, particularly in rural areas — the all-subcutaneous option removes a real logistical barrier. Conversely, some patients and clinicians prefer the certainty of IV administration during the critical induction phase. Having both options available within one drug is a genuine practical advantage. The approval specifically covers patients with inadequate response, loss of response, or intolerance to corticosteroids, immunomodulators, or biologic therapy including TNF blockers. That language directly addresses the Remicade-failure population. What we do not yet have for guselkumab is a head-to-head trial against risankizumab in Crohn’s disease. Until that data exists, the choice between these two IL-23 inhibitors will often come down to dosing preferences, insurance formulary placement, and individual clinician experience. Patients who are weighing these two should ask their gastroenterologist specifically about long-term maintenance data, since the FORTIFY results for risankizumab at 52 weeks remain an advantage until comparable long-term guselkumab data matures.
Rinvoq — An Oral Alternative That Is Not a Biologic
Upadacitinib, branded as Rinvoq, occupies a unique position in the post-Remicade landscape because it is not a biologic at all. It is a small-molecule JAK inhibitor taken as an oral pill, which for some patients represents a welcome departure from injections and infusions. Its mechanism — blocking Janus kinase enzymes that transmit signals from multiple inflammatory cytokines — means it has a broader immunosuppressive effect than any single-target biologic. That breadth is both its strength and the source of its safety considerations. The efficacy data is strong. In the U-EXCEL induction trial, 49.5 percent achieved clinical remission versus 29.1 percent on placebo, with endoscopic response rates of 45.5 percent versus 13.1 percent. The U-EXCEED trial, enriched for biologic-failure patients, showed 38.9 percent clinical remission versus 21.1 percent, with endoscopic response of 34.6 percent versus a striking 3.5 percent on placebo.
At one year in U-ENDURE, 47.6 percent on the 30 milligram maintenance dose maintained clinical remission versus 15.1 percent on placebo. Real-world data has reinforced these findings: a 2024 UK study of 93 patients, 98 percent of whom had prior anti-TNF exposure and 41 percent of whom had failed three or more drug classes, still showed meaningful response. A separate multicenter real-world study reported 52.1 percent clinical remission at 12 weeks and 55.9 percent at six months. The tradeoff is the safety profile. JAK inhibitors carry boxed warnings for serious infections, cardiovascular events, thrombosis, malignancy, and mortality based on data from rheumatoid arthritis trials in older patients with cardiovascular risk factors. Whether these risks translate directly to the younger, generally healthier Crohn’s disease population is still being studied, but they cannot be dismissed. Rinvoq is typically not the first choice for patients over 65 or those with significant cardiovascular risk. For younger patients who have failed biologics and strongly prefer an oral medication, however, the risk-benefit calculus can favor upadacitinib — particularly when the alternative is uncontrolled disease heading toward surgery.
Why Switching TNF Blockers After Remicade Usually Falls Short
One of the most common mistakes in managing Crohn’s disease after Remicade failure is simply trying another TNF blocker. A patient loses response to infliximab, so the next step is adalimumab or certolizumab pegol. This approach is understandable — it is familiar, it is what was available for years, and insurance companies sometimes mandate it before approving newer agents. But the clinical rationale is weak, and the data bears this out. When a patient fails Remicade due to pharmacokinetic reasons — developing anti-drug antibodies that reduce the drug’s effectiveness rather than true pharmacodynamic failure — there is a modest argument for trying another anti-TNF agent with a different molecular structure. But when the failure is primary nonresponse, meaning the patient never improved meaningfully, then the TNF-alpha pathway is likely not the dominant driver of that individual’s disease.
Switching to another TNF blocker in that scenario is treating the same target that already proved insufficient. Network meta-analyses informing the 2026 guidelines have confirmed what many clinicians suspected: switching mechanism of action yields significantly better outcomes than cycling within the TNF class for most patients. The practical challenge is that insurance step-therapy protocols do not always reflect this evidence. Patients may need to appeal for access to IL-23 inhibitors or JAK inhibitors if their plan requires a second TNF failure before covering a different class. Gastroenterologists who specialize in inflammatory bowel disease are generally aware of how to navigate these appeals, and advocacy organizations like the Crohn’s and Colitis Foundation provide resources for patients fighting denials. The point worth emphasizing: if your physician recommends switching to a different mechanism rather than another TNF blocker, the evidence supports that approach, even if the insurance pathway creates temporary friction.
Entyvio and Stelara — Still in the Picture, But No Longer Front of the Line
Vedolizumab, sold as Entyvio, and ustekinumab, sold as Stelara, remain FDA-approved and widely prescribed for Crohn’s disease. Entyvio targets the alpha-4-beta-7 integrin, making it gut-selective — a feature that gives it a favorable safety profile since it primarily affects immune trafficking to the intestine rather than systemically. For patients where safety is the dominant concern, particularly older adults or those with a history of serious infections, Entyvio remains a reasonable consideration after TNF failure. Stelara, which blocks both IL-12 and IL-23, was long considered the default second-line biologic after TNF failure.
The SEQUENCE trial has complicated that positioning. With risankizumab achieving nearly double the endoscopic remission rate of ustekinumab in anti-TNF-experienced patients, Stelara is no longer the top-ranked option in this population according to recent network meta-analyses. It still works for some patients, and those who are currently stable on Stelara should not switch based on trial data alone — stable disease is its own form of success. But for new treatment decisions after Remicade failure, the evidence now points toward the selective IL-23 inhibitors and JAK inhibitors as stronger first choices.
Where Crohn’s Treatment Is Headed After Remicade Failure
The broader trajectory in Crohn’s disease management is toward precision — matching patients to the right mechanism based on biomarkers, disease phenotype, and prior treatment history rather than following a rigid ladder. Several trials are exploring combination strategies that pair biologics with different mechanisms, and biomarker-guided treatment selection studies are underway that could eventually tell clinicians which pathway is dominant in a given patient before the first drug is prescribed. For now, the practical reality for someone whose Remicade has failed is considerably better than it was even three years ago.
Risankizumab has the deepest evidence in this population and was ranked the top drug for both induction and maintenance in anti-TNF-experienced patients in recent network meta-analyses. Guselkumab adds a flexible dosing alternative within the same IL-23 class. Upadacitinib provides an oral option for patients who have exhausted injectable and infusion-based therapies. The field has moved from having one or two imperfect fallbacks to having a genuine menu of mechanistically distinct options — and the data to support informed choices among them.
Conclusion
The central message for anyone dealing with Remicade failure in Crohn’s disease is that losing response to one biologic does not mean biologics as a category have failed. It means the specific pathway that Remicade targets — TNF-alpha — is not adequately controlling the disease, and a different mechanism is needed. The IL-23 inhibitors risankizumab and guselkumab, along with the JAK inhibitor upadacitinib, now offer the strongest evidence-based alternatives, with risankizumab carrying the most compelling head-to-head data in this exact patient population. The next step for any patient in this situation is a frank conversation with a gastroenterologist, ideally one specializing in inflammatory bowel disease, about which mechanism to try next.
That discussion should weigh the clinical data, the patient’s disease history and phenotype, safety considerations, dosing preferences, and the realities of insurance coverage. The options exist. The evidence is substantial. What matters now is matching the right drug to the right patient — and not settling for the reflexive move of simply trying another TNF blocker when the science says otherwise.
Frequently Asked Questions
What should I try after Remicade fails for Crohn’s disease?
Current 2026 treatment guidelines recommend switching to a different mechanism of action rather than trying another TNF blocker. The strongest evidence supports risankizumab (Skyrizi), guselkumab (Tremfya), or upadacitinib (Rinvoq) as next-line options. Risankizumab has the most head-to-head data in Remicade-failure patients, with the SEQUENCE trial showing it nearly doubled endoscopic remission rates compared to ustekinumab.
Is Skyrizi better than Stelara after Remicade stops working?
In the SEQUENCE trial published in the New England Journal of Medicine, risankizumab achieved endoscopic remission in 31.8 percent of anti-TNF-failure patients at week 48, compared to 16.2 percent for ustekinumab. Clinical remission rates were 60.8 percent versus 40.8 percent. Based on this head-to-head comparison, risankizumab appears to be the superior choice in this population, though individual responses can vary.
Can I take a pill instead of injections for Crohn’s disease?
Yes. Upadacitinib (Rinvoq) is an oral JAK inhibitor approved for moderate-to-severe Crohn’s disease. It showed clinical remission rates of 38.9 to 49.5 percent in induction trials. However, it carries a boxed warning for serious infections, cardiovascular events, and other risks, so it requires careful discussion with your doctor about whether the convenience of oral dosing aligns with your individual risk profile.
What is the newest biologic approved for Crohn’s disease?
Guselkumab (Tremfya) received FDA approval for moderately to severely active Crohn’s disease on March 20, 2025. It is an IL-23 inhibitor that offers both subcutaneous and intravenous induction options, making it the most flexible IL-23 inhibitor currently available for Crohn’s. Its GALAXI trials showed 47 percent clinical remission at week 12 in both studies.
Why do doctors no longer recommend switching to another TNF blocker after Remicade?
When Remicade fails, the underlying issue is often that TNF-alpha is not the primary driver of that patient’s inflammation. Switching to adalimumab or certolizumab targets the same pathway with predictably diminished returns. Network meta-analyses and updated guidelines now show that switching to a different mechanism — IL-23 inhibition or JAK inhibition — yields significantly better outcomes for most patients than cycling within the TNF class.
How effective is Rinvoq in patients who have failed multiple treatments?
A real-world UK study of 93 patients, where 98 percent had prior anti-TNF exposure and 41 percent had failed three or more drug classes, found that upadacitinib still achieved meaningful clinical responses. A separate multicenter study reported 52.1 percent clinical remission at 12 weeks and 55.9 percent at six months, suggesting it retains efficacy even in heavily pretreated patients.
